22131-35-7

Basic information

• Product Name: butalamine
• Synonyms: butalamine;5-[2-(Dibutylamino)ethylamino]-3-phenyl-1,2,4-oxadiazole;3-Phenyl-5-(dibutylaMinoethylaMino)-1,2,4-oxadiazole;N,N-Dibutyl-N'-(3-phenyl-1,2,4-oxadiazol-5-yl)-1,2-ethanediaMine;N1,N1-Dibutyl-N2-(3-phenyl-1,2,4-oxadiazol-5-yl)-1,2-ethanediaMi
• CAS NO: 22131-35-7
• Molecular Formula: C₁₈H₂₈N₄O
• Molecular Weight: 316.44
• EINECS: 244-794-9
• Mol File: 22131-35-7.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 437.5°Cat760mmHg
• Flash Point: 218.4°C
• Appearance: /
• Density: 1.057g/cm³
• Vapor Pressure: 7.43E-08mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: Refrigerator
• Solubility: Chloroform )Slightly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: butalamine(CAS DataBase Reference)
• NIST Chemistry Reference: butalamine(22131-35-7)
• EPA Substance Registry System: butalamine(22131-35-7)

Safety Data

• Hazardous Substances Data: 22131-35-7(Hazardous Substances Data)

Usage

Description

Butalamine is a vasodilator with peripheral action and local anesthetic properties. It has been demonstrated to inhibit state 3 respiration and decrease ADP/O in rat liver, indicating its potential effects on cellular metabolism and energy production.

Uses

Used in Pharmaceutical Industry:
Butalamine is used as a vasodilator for its ability to improve blood flow and reduce peripheral vascular resistance. This can be beneficial in treating conditions where increased blood flow is necessary, such as in cases of hypertension or other circulatory issues.
Additionally, butalamine is used as a local anesthetic due to its numbing effect on tissues. This makes it a valuable compound for use in medical procedures where local pain relief is required, such as in minor surgeries or dental work.
Used in Research Applications:
In the field of scientific research, butalamine is used as a tool to study the effects of vasodilation and local anesthesia on cellular respiration and energy metabolism. Its ability to inhibit state 3 respiration and decrease ADP/O in rat liver provides valuable insights into the mechanisms underlying these processes and can contribute to the development of new therapeutic strategies for various medical conditions.

Originator

Surheme,Aron,France,1969

Manufacturing Process

Benzaldehyde and hydroxylamine may be reacted, the product chlorinated and then reacted with cyanamide to give 5-amino-3-phenyl-1,2,4-oxadiazole. 32 grams of 3-phenyl-5-amino-1,2,4-oxadiazole dissolved in about 150 ml of anhydrous benzene, 7.8 grams of sodium amide are added and the reaction mixture heated at the boiling point with stirring for 2 hours. A solution of 38.3 grams of dibutylaminoethyl chloride in benzene is then added and the mixture heated to boiling under reflux for four hours. The sodium chloride is separated as previously described, the benzene removed by vacuum distillation and 56 grams of 3-phenyl-5-(dibutylaminoethylamino)-1,2,4-oxadiazole is obtained in the form of an oil which is then converted directly to the crystalline hydrochloride. This is accomplished by dissolving the oil in ethanol and adding the stoichiometric equivalent of anhydrous ethyl ether saturated with gaseous hydrogen chloride. The recrystallized salt is found to have a melting point of 145°C.

Therapeutic Function

Vasodilator

InChI:InChI=1/C18H28N4O/c1-3-5-13-22(14-6-4-2)15-12-19-18-20-17(21-23-18)16-10-8-7-9-11-16/h7-11H,3-6,12-15H2,1-2H3,(H,19,20,21)